You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Repeated stereotactic radiosurgery for patients with progressive brain metastases
|
|---|---|
| Published in |
Journal of Neuro-Oncology, September 2015
|
| DOI | 10.1007/s11060-015-1937-4 |
| Pubmed ID | |
| Authors |
Giuseppe Minniti, Claudia Scaringi, Sergio Paolini, Enrico Clarke, Francesco Cicone, Vincenzo Esposito, Andrea Romano, Mattia Osti, Riccardo Maurizi Enrici |
| Abstract |
In the present study we have evaluated the efficacy and toxicity of repeated stereotactic radiosurgery (SRS) in patients with recurrent/progressive brain metastases. Between March 2006 and October 2014, 43 patients (21 men and 22 women) with 47 lesions received a second course of SRS given in three daily fractions of 7-8 Gy. With a follow-up study of 19 months, the 1- and 2-year survival rates from repeated SRS were 37 and 20 %, respectively, and the 1- and 2-year local control rates were 70 and 60 %, respectively. Actuarial local control was significantly better for breast and lung metastases as compared with melanoma metastases; specifically, 1-year local control rates were 38 % for melanoma, 78 % for breast carcinoma and 73 % for non-small cell lung cancer (NSCLC) metastases (p = 0.01). The cause of death was progressive systemic disease in 25 patients and progressive brain disease in 11 patients. Stable extracranial disease (p = 0.01) and Karnofsky performance status (KPS; p = 0.03) were predictive of longer survival. Radiologic changes suggestive of brain radionecrosis were observed in 9 (19 %) out of 47 lesions, with an actuarial risk of 34 % at 12 months. Neurological deficits (RTOG Grade 2 or 3) associated with brain necrosis occurred in 14 % of patients. In conclusion, a second course of SRS given in three daily fractions is a feasible treatment for selected patients with recurrent/progressive brain metastases. Further studies are needed to explore the efficacy and safety of different dose-fractionation schedules, especially in patients with melanoma or large metastases. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 82 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 1 | 1% |
| Unknown | 81 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 12 | 15% |
| Researcher | 11 | 13% |
| Student > Ph. D. Student | 8 | 10% |
| Student > Master | 7 | 9% |
| Student > Bachelor | 5 | 6% |
| Other | 15 | 18% |
| Unknown | 24 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 33 | 40% |
| Neuroscience | 6 | 7% |
| Nursing and Health Professions | 3 | 4% |
| Biochemistry, Genetics and Molecular Biology | 2 | 2% |
| Physics and Astronomy | 2 | 2% |
| Other | 7 | 9% |
| Unknown | 29 | 35% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 September 2015.
All research outputs
#17,773,420
of 22,828,180 outputs
Outputs from Journal of Neuro-Oncology
#2,117
of 2,970 outputs
Outputs of similar age
#181,031
of 268,597 outputs
Outputs of similar age from Journal of Neuro-Oncology
#28
of 76 outputs
Altmetric has tracked 22,828,180 research outputs across all sources so far. This one is in the 19th percentile – i.e., 19% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,970 research outputs from this source. They receive a mean Attention Score of 4.2. This one is in the 24th percentile – i.e., 24% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 268,597 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 27th percentile – i.e., 27% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 76 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 52% of its contemporaries.